Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primer. 2015; 1: 15069. doi: 10.1038/nrdp.2015.69
DiBonaventura, M, Gabriel, S, Dupclay, L, et al.. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12(1): 20. doi: 10.1186/1471-244X-12-20
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management.. Nice Guidelines. https://www.nice.org.uk/guidance/cg178. Accessed June 27, 2019.
Kane, JM, Correll, CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010; 12(3): 345–357.
Leucht, S, Leucht, C, Huhn, M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017; 174(10): 927–942. doi: 10.1176/appi.ajp.2017.16121358
Leucht, S, Tardy, M, Komossa, K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet Lond Engl. 2012; 379(9831): 2063–2071. doi: 10.1016/S0140-6736(12)60239-6
Kishimoto, T, Agarwal, V, Kishi, T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18(1): 53–66. doi: 10.1038/mp.2011.143
Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018; 17(2): 149–160. doi: 10.1002/wps.20516
Kishimoto, T, Hagi, K, Nitta, M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019; 18(2): 208–224.
Lieberman, JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007; 68(2): e04. doi: 10.4088/JCP.0207e04
Lim, SS, Vos, T, Flaxman, AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–2260. doi: 10.1016/S0140-6736(12)61766-8
Murray, CJL, Vos, T, Lozano, R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2197–2223. doi: 10.1016/S0140-6736(12)61689-4
Vos, T, Flaxman, AD, Naghavi, M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2163–2196. doi: 10.1016/S0140-6736(12)61729-2
Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 2129–2143. doi: 10.1016/S0140-6736(12)61680-8
Correll, CU. The prevalence of negative symptoms in schizophrenia and their impact on patient functioning and course of illness. J Clin Psychiatry. 2013; 74(2): e04.
Insel, TR. Rethinking schizophrenia. Nature. 2010; 468(7321): 187–193. doi: 10.1038/nature09552
McGorry, PD, Yung, AR, Bechdolf, A, et al. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry. 2008; 65(1): 25–27. doi: 10.1001/archgenpsychiatry.2007.9
Mosolov, SN, Potapov, AV, Ushakov, UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Ann Gen Psychiatry. 2012; 11: 1. doi: 10.1186/1744-859X-11-1
Millan, MJ, Fone, K, Steckler, T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645–692. doi: 10.1016/j.euroneuro.2014.03.008
Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 38–52; quiz 35–37, 53. doi: 10.1017/S1092852914000601
Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7): 675–684. doi: 10.1001/jamapsychiatry.2017.0624
Solmi, M, Murru, A, Pacchiarotti, I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13: 757–777. doi: 10.2147/TCRM.S117321
Correll, CU, Detraux, J, De Lepeleire, J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015; 14(2): 119–136. doi: 10.1002/wps.20204
Carbon, M, Kane, JM, Leucht, S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018; 17(3): 330–340. doi: 10.1002/wps.20579
Carbon, M, Hsieh, C-H, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78(3): e264–e278. doi: 10.4088/JCP.16r10832
Vancampfort, D, Firth, J, Correll, CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019; 18(1): 53–66. doi: 10.1002/wps.20614
Correll, CU, Solmi, M, Veronese, N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017; 16(2): 163–180. doi: 10.1002/wps.20420
Vancampfort, D, Correll, CU, Galling, B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016; 15(2): 166–174. doi: 10.1002/wps.20309
Vancampfort, D, Stubbs, B, Mitchell, AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015; 14(3): 339–347. doi: 10.1002/wps.20252
Nielsen, J, Correll, CU, Manu, P, et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013; 74(6): 603–613; quiz 613. doi: 10.4088/JCP.12r08064
Siskind, D, Siskind, V, Kisely, S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry Rev Can Psychiatry. 2017; 62(11): 772–777. doi: 10.1177/0706743717718167
Howes, OD, McCutcheon, R, Agid, O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174(3): 216–229. doi: 10.1176/appi.ajp.2016.16050503
Yang, AC, Tsai, S-J. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017; 18(8): 1689. doi: 10.3390/ijms18081689
Garay, RP, Citrome, L, Samalin, L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016; 17(7): 921–936. doi: 10.1517/14656566.2016.1149164
Köster, L-S, Carbon, M, Correll, CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014; 19(4): 511–531. doi: 10.1517/14728214.2014.958148
Kane, JM, Kishimoto, T, Correll, CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216–226. doi: 10.1002/wps.20060
Kishimoto, T, Hagi, K, Nitta, M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018; 44(3): 603–619. doi: 10.1093/schbul/sbx090
Misawa, F, Kishimoto, T, Hagi, K, et al Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016; 176(2–3): 220–230. doi: 10.1016/j.schres.2016.07.018
Haddad, PM, Kishimoto, T, Correll, CU, et al. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015; 28(3): 216–221. doi: 10.1097/YCO.0000000000000160
Kishimoto, T, Nitta, M, Borenstein, M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957–965. doi: 10.4088/JCP.13r08440
Kane, JM, Kishimoto, T, Correll, CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013; 66(Suppl 8): S37–S41. doi: 10.1016/j.jclinepi.2013.01.012
Kishimoto, T, Robenzadeh, A, Leucht, C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40(1): 192–213. doi: 10.1093/schbul/sbs150
Ibeas Bih, C, Chen, T, Nunn, AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurother J Am Soc Exp Neurother. 2015; 12(4): 699–730. doi: 10.1007/s13311-015-0377-3
White, CM. A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019; 59: 923–934. doi: 10.1002/jcph.1387
Leweke, FM, Mueller, JK, Lange, B, et al. Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. CNS Drugs. 2018; 32(7): 605–619. doi: 10.1007/s40263-018-0539-z
McGuire, P, Robson, P, Cubala, WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018; 175(3): 225–231. doi: 10.1176/appi.ajp.2017.17030325
Sokoloff, P, Le Foll, B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017; 45(1): 2–19. doi: 10.1111/ejn.13390
Bitter, I, Lieberman, JA, Gaudoux, F, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019. doi: 10.1038/s41386-019-0355-2
Davis, RE, Correll, CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016; 16(6): 601–614. doi: 10.1080/14737175.2016.1174577
Vanover, KE, Dimitrienko, A, Glass, SJ, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: overview of placebo-controlled clinical trials and an open-label safety switching study. APA Conf Poster Present P5-178, San Francisco, USA, 2018.
Snyder, GL, Vanover, KE, Zhu, H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 2015; 232(3): 605–621. doi: 10.1007/s00213-014-3704-1
Lieberman, JA, Davis, RE, Correll, CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016; 79(12): 952–961. doi: 10.1016/j.biopsych.2015.08.026
Vanover, KE, O’Gorman, C, Glass, SJ, et al. Favorable clinical safety profile for lumateperone (ITI-007) switching from standard-of-care antipsychotic therapy in patients with schizophrenia. ACNP Conf 2017 Poster Present T189, California, USA.
Vanover, KE, Correll, CU, Weingart, M, et al. Long-term safety for lumateperone (ITI-007) in the treatment of schizophrenia. ACNP Conf 2018 Poster Present T184, Hollywood, USA.
Grauer, SM, Pulito, VL, Navarra, RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009; 331(2): 574–590. doi: 10.1124/jpet.109.155994
Suzuki, K, Harada, A, Suzuki, H, et al. TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology. 2016; 41(9): 2252–2262. doi: 10.1038/npp.2016.20
Macek, TA, McCue, M, Dong, X, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019; 204:289–294. doi: 10.1016/j.schres.2018.08.028
Crippa, JA, Hallak, JEC, Abílio, VC, et al. Cannabidiol and sodium nitroprusside: two novel neuromodulatory pharmacological interventions to treat and prevent psychosis. CNS Neurol Disord Drug Targets. 2015; 14(8): 970–978.
Hallak, JEC, Maia-de-Oliveira, JP, Abrao, J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013; 70(7): 668–676. doi: 10.1001/jamapsychiatry.2013.1292
Wang, X, Zhao, J, Hu, Y, et al. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychiatry Res. 2018; 269:271–277. doi: 10.1016/j.psychres.2018.08.079
Stone, JM, Morrison, PD, Koychev, I, et al. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychol Med. 2016; 46(16): 3443–3450. doi: 10.1017/S0033291716002245
Brown, HE, Freudenreich, O, Fan, X, et al. Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2019; 76(7): 691–699.
Maia-de-Oliveira, JP, Baker, GB, Dursun, SM, et al. Letter to the editor: sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained? Psychol Med. 2017; 47(5): 981–982. doi: 10.1017/S003329171600307X
Schwartz, MD, Canales, JJ, Zucchi, R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018; 22(6): 513–526. doi: 10.1080/14728222.2018.1480723
Revel, FG, Moreau, J-L, Pouzet, B, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013; 18(5): 543–556. doi: 10.1038/mp.2012.57
Espinoza, S, Leo, D, Sotnikova, TD, et al. Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397. Front Pharmacol. 2018; 9: 645. doi: 10.3389/fphar.2018.00645
Fowler, S, Kletzl, H, Finel, M, et al. A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015; 352(2): 358–367. doi: 10.1124/jpet.114.220194
Poola, N, Sunkaraneni, S, Galluppi, G, et al. Pharmacokinetics, safety and tolerability of SEP-363856 in healthy adult male subjects and in adult patients with schizophrenia following oral administration. Poster Present. 2018; American College of Neuropsychopharmacology, Hollywood, FL, USA.
Umbricht, D, Alberati, D, Martin-Facklam, M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014; 71(6): 637–646. doi: 10.1001/jamapsychiatry.2014.163
Bugarski-Kirola, D, Blaettler, T, Arango, C, et al. Bitopertin in negative symptoms of schizophrenia – results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry. 2017; 82(1): 8–16. doi: 10.1016/j.biopsych.2016.11.014
Meltzer, HY, Elkis, H, Vanover, K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012; 141(2–3): 144–152. doi: 10.1016/j.schres.2012.07.029
Keefe, RSE, Harvey, PD, Khan, A, et al. Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. J Clin Psychiatry. 2018; 79(3): 17m11753. doi: 10.4088/JCP.17m11753
Davidson, M, Saoud, J, Staner, C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017; 174(12): 1195–1202. doi: 10.1176/appi.ajp.2017.17010122
Staner, C, Davidson, M, Noel, N, et al. Results of an exploratory phase 2a study with MIN-101, a 5-HT2A/sigma-2 antagonist, for the treatment of schizophrenia. Present Sixth Bienn Schizophr Int Res Soc Conf Florence. 2016.
Sacchi, S, Rosini, E, Pollegioni, L, et al. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des. 2013; 19(14): 2499–2511.
Keefe, RSE, Meltzer, HA, Dgetluck, N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. 2015; 40(13): 3053–3060. doi: 10.1038/npp.2015.176
Hashimoto, K, Malchow, B, Falkai, P, et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013; 263(5): 367–377. doi: 10.1007/s00406-013-0399-y
Moschetti, V, Desch, M, Goetz, S, et al. Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study. Eur J Drug Metab Pharmacokinet. 2018; 43(2): 239–249. doi: 10.1007/s13318-017-0440-z
Boggs, DL, Surti, T, Gupta, A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018; 235(7): 1923–1932. doi: 10.1007/s00213-018-4885-9
Lin, C-H, Lin, C-H, Chang, Y-C, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018; 84(6): 422–432. doi: 10.1016/j.biopsych.2017.12.006
Lane, H-Y, Lin, C-H, Green, MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013; 70(12): 1267–1275. doi: 10.1001/jamapsychiatry.2013.2159
Correll, CU, Citrome, L, Haddad, PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016; 77(Suppl 3): 1–24. doi: 10.4088/JCP.15032su1
Alkermes, Incl., Data on file. Clinical Study Report ALK9072-B102. Walth MA. 2017.
Hard, ML, Wehr, AY, Sadler, BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 2018; 43(4): 461–469. doi: 10.1007/s13318-018-0488-4
Walling, D, Hard, ML, Wehr, A, et al. Aripiprazole lauroxil nanocrystal dispersion: a potential 1-day initiation regimen for long-acting aripiprazole lauroxil. Present Annu Meet Am Psychiatr Assoc. 2018.
Mathews, M, Gopal, S, Nuamah, I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019; 15: 1365–1379. doi: 10.2147/NDT.S197225
Citrome, L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERISTM) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses. 2018; 12(3): 130–141. doi: 10.3371/CSRP.CI.101118
Patel, DB. A review on atrigel drug delivery system. J Global Pharma Technol. 2010; 2:85–90.
Gomeni, R, Heidbreder, C, Fudala, PJ, et al. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol. 2013; 53(10): 1010–1019. doi: 10.1002/jcph.141
Laffont, CM, Gomeni, R, Zheng, B, et al. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014; 53(6): 533–543. doi: 10.1007/s40262-014-0132-7
Isitt, JJ, Nadipelli, VR, Kouassi, A, et al. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016; 174(1–3): 126–131. doi: 10.1016/j.schres.2016.03.020
Nasser, AF, Henderson, DC, Fava, M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016; 36(2): 130–140. doi: 10.1097/JCP.0000000000000479
Ivaturi, V, Gopalakrishnan, M, Gobburu, JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting atrigel formulation of risperidone: E–R analysis of RBP-7000, a long acting risperidone formulation. Br J Clin Pharmacol. 2017; 83(7): 1476–1498. doi: 10.1111/bcp.13246
Graham, J, Fava, M, Newcomer, J, et al. Monthly extended-release risperidone injections (RBP-7000) in the treatment of schizophrenia: results from two phase III trials. Present Annu Meet Am Psychiatr Assoc. 2018.
Solmi, M, Pigato, G, Kane, JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12: 1215–1238. doi: 10.2147/DDDT.S133205
Correll, CU, Manu, P, Olshanskiy, V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA J Am Med Assoc. 2009; 302(16): 1765–1773. doi: 10.1001/jama.2009.1549
De Hert, M, Detraux, J, van Winkel, R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2): 114–126. doi: 10.1038/nrendo.2011.156
Correll, CU, Lencz, T, Malhotra, AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17(2): 97–107. doi: 10.1016/j.molmed.2010.10.010
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet Lond Engl. 2013; 382(9896): 951–962. doi: 10.1016/S0140-6736(13)60733-3
Lieberman, JA, Stroup, TS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223. doi: 10.1056/NEJMoa051688
Wentland, MP, Lou, R, Lu, Q, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009; 19(8): 2289–2294. doi: 10.1016/j.bmcl.2009.02.078
Silverman, BL, Martin, W, Memisoglu, A, et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018; 195: 245–251. doi: 10.1016/j.schres.2017.10.014
Sun, L, McDonnell, D, von Moltke, L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018; 40(11): 1845–1854.e2. doi: 10.1016/j.clinthera.2018.09.002
Martin, WF, Correll, CU, Weiden, PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019; 176: 457–467. doi: 10.1176/appi.ajp.2018.18030280
Correll, C, Kahn, R, Silverman, B, et al. Combination of olanzapine and samidorphan limits the weight gain observed with olanzapine alone: results from the phase 3 ENLIGHTEN-2 schizophrenia study. Presented at the Schizophrenia International Research Society (SIRS) meeting; April 10, 2019; Orlando, Florida, USA.
Potkin, SG, Kunovac, J, Silverman, BL, et al. 26 A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia. CNS Spectr. 2019; 24(1): 187–188. doi: 10.1017/S1092852919000208
Correll, CU, What are we looking for in new antipsychotics? J Clin Psychiatry. 2011; 72(Suppl 1): 9–13. doi: 10.4088/JCP.10075su1.02
Correll, CU, Vanover, KE, Glass, SJ, et al. Favorable clinical safety profile for lumateperone 8ITI-007 – switching from standard-of-care (SOC) antipsychotic therapy in patients with schizophrenia. CINP Conf 2018 Poster Present PM161, Vienna Austria.